A detailed history of Lindbrook Capital, LLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 126 shares of RYTM stock, worth $6,470. This represents 0.0% of its overall portfolio holdings.

Number of Shares
126
Previous 97 29.9%
Holding current value
$6,470
Previous $4,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$35.41 - $44.37 $1,026 - $1,286
29 Added 29.9%
126 $5,000
Q4 2023

Jan 31, 2024

BUY
$21.39 - $49.64 $812 - $1,886
38 Added 64.41%
97 $4,000
Q3 2023

Oct 25, 2023

BUY
$15.81 - $27.8 $932 - $1,640
59 New
59 $1,000
Q2 2022

Aug 01, 2022

SELL
$3.12 - $12.25 $1,382 - $5,426
-443 Closed
0 $0
Q1 2022

Apr 21, 2022

BUY
$6.13 - $12.24 $2,206 - $4,406
360 Added 433.73%
443 $5,000
Q4 2021

Jan 18, 2022

BUY
$8.62 - $13.9 $715 - $1,153
83 New
83 $1,000
Q2 2021

Jul 27, 2021

SELL
$18.52 - $22.55 $870 - $1,059
-47 Closed
0 $0
Q2 2020

Jul 27, 2020

SELL
$14.41 - $25.35 $115 - $202
-8 Reduced 14.55%
47 $1,000
Q1 2020

Apr 22, 2020

BUY
$13.16 - $22.9 $723 - $1,259
55 New
55 $1,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $2.86B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.